

University of Dundee

The Genetics of Adverse Drug Outcomes in Type 2 Diabetes

Baye, Assefa M.; Fanta, Teferi G.; Siddiqui, Moneeza K.; Dawed, Adem Y.

Published in:
Frontiers in Genetics

DOI:
[10.3389/fgene.2021.675053](https://doi.org/10.3389/fgene.2021.675053)

Publication date:
2021

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Baye, A. M., Fanta, T. G., Siddiqui, M. K., & Dawed, A. Y. (2021). The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review. *Frontiers in Genetics*, 12, [675053].
<https://doi.org/10.3389/fgene.2021.675053>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review

Assefa M. Baye¹, Teferi G. Fanta¹, Moneeza K. Siddiqui² and Adem Y. Dawed^{2*}

¹ Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia, ² Division of Population Health and Genomics, Ninewells Hospital and School of Medicine, University of Dundee, Dundee, United Kingdom

OPEN ACCESS

Edited by:

Celine Verstuyft,
Université Paris-Saclay, France

Reviewed by:

Zhiguo Xie,
Central South University, China
Vera Ribeiro,
University of Algarve, Portugal

*Correspondence:

Adem Y. Dawed
a.y.dawed@dundee.ac.uk

Specialty section:

This article was submitted to
Pharmacogenetics and
Pharmacogenomics,
a section of the journal
Frontiers in Genetics

Received: 02 March 2021

Accepted: 21 May 2021

Published: 14 June 2021

Citation:

Baye AM, Fanta TG, Siddiqui MK and
Dawed AY (2021) The Genetics of
Adverse Drug Outcomes in Type 2
Diabetes: A Systematic Review.
Front. Genet. 12:675053.
doi: 10.3389/fgene.2021.675053

Background: Adverse drug reactions (ADR) are a major clinical problem accounting for significant hospital admission rates, morbidity, mortality, and health care costs. One-third of people with diabetes experience at least one ADR. However, there is notable interindividual heterogeneity resulting in patient harm and unnecessary medical costs. Genomics is at the forefront of research to understand interindividual variability, and there are many genotype-drug response associations in diabetes with inconsistent findings. Here, we conducted a systematic review to comprehensively examine and synthesize the effect of genetic polymorphisms on the incidence of ADRs of oral glucose-lowering drugs in people with type 2 diabetes.

Methods: A literature search was made to identify articles that included specific results of research on genetic polymorphism and adverse effects associated with oral glucose-lowering drugs. The electronic search was carried out on 3rd October 2020, through Cochrane Library, PubMed, and Web of Science using keywords and MeSH terms.

Result: Eighteen articles consisting of 10,383 subjects were included in this review. Carriers of reduced-function alleles of organic cation transporter 1 (OCT 1, encoded by *SLC22A1*) or reduced expression alleles of plasma membrane monoamine transporter (PMAT, encoded by *SLC29A4*) or serotonin transporter (SERT, encoded by *SLC6A4*) were associated with increased incidence of metformin-related gastrointestinal (GI) adverse effects. These effects were shown to exacerbate by concomitant treatment with gut transporter inhibiting drugs. The CYP2C9 alleles, *2 (rs1799853C>T) and *3 (rs1057910A>C) that are predictive of low enzyme activity were more common in subjects who experienced hypoglycemia after treatment with sulfonylureas. However, there was no significant association between sulfonylurea-related hypoglycemia and genetic variants in the ATP-binding cassette transporter sub-family C member 8 (ABCC8)/Potassium Inwardly Rectifying Channel Subfamily J Member 11 (KCNJ11). Compared to the wild type, the low enzyme activity C allele at CYP2C8*3 (rs1057910A>C) was associated with less weight gain whereas the C allele at rs6123045 in the *NFATC2* gene was significantly associated with edema from rosiglitazone treatment.

Conclusion: In spite of limited studies investigating genetics and ADR in diabetes, some convincing results are emerging. Genetic variants in genes encoding drug transporters and metabolizing enzymes are implicated in metformin-related GI adverse effects, and sulfonylurea-induced hypoglycemia, respectively. Further studies to investigate newer antidiabetic drugs such as DPP-4i, GLP-1RA, and SGLT2i are warranted. In addition, pharmacogenetic studies that account for race and ethnic differences are required.

Keywords: pharmacogenomics, type 2 diabetes, adverse drug outcomes, oral glucose-lowering drugs, gastrointestinal side effects, hypoglycemia, weight gain

INTRODUCTION

Diabetes mellitus refers to a group of metabolic disorders characterized by hyperglycemia resulting from insufficient production and/or ineffective response of cells to insulin. It is one of the major contributors to morbidity and mortality globally, and its prevalence continues to rise. By 2019, an estimated 463 million adults aged 20–79 years were living with diabetes which accounts 9.3% of the global population in this age group (International Diabetes Federation, 2019). This figure is expected to surge to 578 million (10.2%) by 2030 and to 700 million (10.9%) by 2045, most of this in the form of type 2 diabetes (T2D) (International Diabetes Federation, 2019). Poorly controlled diabetes progressively leads to chronic microvascular, macrovascular and neuropathic complications which manifest as renal failure, blindness, lower limb amputation, and accelerated vascular disease.

Several drugs are available for the management of T2D, referred to as glucose lowering agents. These include: biguanides (metformin), insulin secretagogues (sulfonylureas, meglitinides), thiazolidinediones, alpha glucosidase inhibitors (acarbose), incretin mimetics (GLP-1RAs, DPP-4is), amylin antagonists, sodium-glucose co-transporter-2 inhibitors (SGLT-2i), and insulin. These classes of drugs are either prescribed as monotherapy or given in combination.

The management of T2D is guided by national and international evidence-based guidelines (Buse et al., 2020), but there is noticeable inter-individual variability in treatment response as defined by glycemic reduction and adverse drug reactions. This variation is the net effect of several environmental and clinical factors including age, sex, adherence, concomitant therapy, drug interactions, and disease severity. In addition to these, a patient's genotype can affect interindividual differences in drug response.

Adverse drug reactions are major clinical and public health problems world-wide. In the UK, around 6.5% of hospital admissions are due to adverse drug reactions (Pirmohamed et al., 2004), and that almost 15% of patients experience an ADR during their admission (Davies et al., 2009, 2010). The projected annual cost of such admissions to the NHS was £466m (Davies et al., 2009). Glucose lowering agents are one of the drugs of great concern for ADRs (Ducoffe et al., 2016). They have a well-described set of ADRs that are detrimental to individuals' health and quality of life (Table 1). In the US, from 2010 to 2013, there were 600,991 ADRs associated with glucose-lowering agents with

an average hospital marginal cost of \$4,312 resulting in an annual hospital cost of \$2.59 billion (Spector et al., 2017). Optimizing drug therapy through the avoidance of ADRs will dramatically improve patient health while generating millions of dollars by saving unnecessary medical costs.

However, there is inter-individual variability in the type and severity of ADRs experienced by individuals taking glucose-lowering drugs. While clinical and environmental factors influence this, genomic factors are also important. Here, we aim to undertake a systematic review of pharmacogenomic studies of ADRs related to oral glucose-lowering drugs.

METHODS

This systematic review is reported according to the Preferred Reporting Items for the Systematic Reviews and Meta-analysis Protocols (PRISMA-P) 2015 Checklist (Shamseer et al., 2015).

Type of Participants

Participants included in eligible studies must be diagnosed with T2D and treated with oral glucose-lowering drugs.

Type of Exposure

We included studies in which participants genotype were investigated in relation to ADRs of oral glucose-lowering agents.

Outcomes

The primary outcome was the incidence of any of the adverse effects of glucose-lowering drugs (Table 1). For metformin, GI adverse effects were considered - hypoglycemia and weight gain for sulfonylureas and weight gain and edema for thiazolidinediones.

Eligibility Criteria

Inclusion Criteria

Studies assessing the effect of genetic variations on the incidence of adverse effects of oral glucose-lowering drugs in people with T2D, published up to 3rd October 2020 in English language without any geographical restriction were included in this review.

Exclusion Criteria

We did not consider news, qualitative studies, case reports, reviews, editorials, and comments; and all non-published studies and published in non-English languages. Studies in which relevant data on genetic polymorphisms and/or ADRs associated

TABLE 1 | List of adverse drug reactions related to glucose-lowering drugs in type 2 diabetes.

Drug	Side effects	Comments
Metformin	GI side effects (10%–25%): nausea, indigestion, abdominal cramp or bloating, or combination of these (Bailey and Turner, 1996; Goodman, 2017). Decrease in vitamin B12 concentration (5 to 10%) (Bell, 2010; de Jager et al., 2010; Aroda et al., 2016; Donnelly et al., 2020) Lactic acidosis (Misbin, 2004)	Symptoms are usually mild, transient, and reversible after dose reduction. When severe requires drug switch in about 5% of the population. Patient may develop anemia and/or peripheral neuropathy (Bell, 2010). Rare but serious
Thiazolidinediones	Increased risk of overweight, congestion, heart failure, fractures, bladder cancer (pioglitazone) and myocardial infarction (rosiglitazone) (Jearath et al., 2016).	An average of 2 to 4 kg weight gain in the first year of treatment (Yki-Järvinen, 2004; Winkelmayer et al., 2008). Higher risk of adverse cardiovascular events with rosiglitazone (Winkelmayer et al., 2008; Juurlink et al., 2009; Graham et al., 2010).
Sulfonylurea and meglitinides	Hypoglycemia including coma (Schopman et al., 2014). Weight gain of 1–3 kg (Meneilly, 2011; Guardado-Mendoza et al., 2013)	
GLP-1 analogs	Nausea and vomiting, injection site reactions	Could be mediated through neural activation of specific CNS neurons due to peripheral dosing of peptide (Madsbad et al., 2011).
DPP-4 inhibitors	Headache, nasopharyngitis, and urinary tract infections (sitagliptin) (Katzung et al., 2019).	Have no effects on body weight or risk of hypoglycemia (Salvo et al., 2016).
SGLT2 inhibitors	Genital and urinary tract infections. IV volume depression and hypotension can result from osmotic diuresis (Katzung et al., 2019).	

with oral glucose-lowering agents is lacking or impossible to extract were also excluded.

Search Strategy for Identifying Relevant Studies

A literature search was made to identify articles that included specific results of research on genetic polymorphisms and adverse effects associated with oral glucose-lowering agents. The electronic search was carried out on 3rd October 2020, through Cochrane Library, PubMed, and Web of Science using keywords and MeSH terms with no restriction for time of publication. The search strategy conducted in MEDLINE via PubMed, Cochrane, and Web of Science is shown in **Supplementary Material**. We also manually searched reference lists from relevant studies and contact experts in the field in order to identify additional eligible studies.

Selection of Studies for Inclusion in the Review

Two review authors (AMB and AYD) independently identified articles and then screened their titles and abstracts for eligibility. Thereafter, full texts of articles considered to be eligible were retrieved. Furthermore, the review authors independently assessed the eligibility for inclusion in the review based on the inclusion and exclusion criteria. Disagreements between the two authors was resolved by consensus. A PRISMA flow diagram (Shamseer et al., 2015) was employed to document the process of literature selection and the reasons for exclusion of articles were stated.

Data Extraction and Management

Two review authors (AMB and AYD) independently extracted data from the articles reviewed. A data extraction form for this purpose was designed. Data was collected on the first author's name, year of publication, geographical location (country where the study was performed), sample size, population characteristics, relevant genetic polymorphism, primary outcome measurements (incidence of adverse events after treatment with oral glucose-lowering agents). Any disagreements between the two review authors were resolved through discussion and consensus.

Study characteristics and the effect estimates of genetic polymorphisms on the incidence of adverse effects of oral glucose-lowering agents was presented in full, in tabular form. We summarized findings based on the type of oral glucose-lowering agent.


RESULT

Study Selection

Of the 362 studies identified, 66 were included for review of the full text. Of these studies, 18 studies met the inclusion criteria (**Figure 1**).

Characteristics of Included Studies

Eighteen articles comprised of 10, 383 subjects were included in this review (**Table 2**). Among these, two studies were multinational (Bailey et al., 2010; Dawed et al., 2019). While 12 studies were conducted in Europe (Holstein et al., 2005, 2011, 2012; Ragia et al., 2009, 2012, 2014; Tarasova et al., 2012; Dujic et al., 2015, 2016a,b, 2018; Dawed et al., 2016), three were in Asia



(Kahn et al., 2006; Sato et al., 2010; Gökalp et al., 2011) and one was in the US (Ruaño et al., 2009).

Five of these studies comprising of 5,438 subjects were conducted to investigate association between genetic polymorphisms and metformin-related GI adverse effects (Tarasova et al., 2012; Dujic et al., 2015, 2016a,b; Dawed et al., 2019). Association between genetic polymorphisms and the risks of sulfonylurea-induced hypoglycemia was evaluated in nine studies comprising of 1,944 subjects (Holstein et al., 2005, 2011, 2012; Ragia et al., 2009, 2012, 2014; Sato et al., 2010; Gökalp et al., 2011; Dujic et al., 2018). Among the sulfonylureas, glimepiride was the most investigated (nine studies) (Holstein et al., 2005, 2012; Ragia et al., 2009, 2012, 2014; Sato et al., 2010; Gökalp et al., 2011; Dujic et al., 2018) followed by gliclazide (Ragia et al., 2009, 2012, 2014; Gökalp et al., 2011; Dujic et al., 2018) (five studies) and glibenclamide (Holstein et al., 2005, 2011, 2012; Sato et al., 2010; Dujic et al., 2018) (five studies). Four studies consisting of 3,001 subjects evaluated the genetics of thiazolidinediones-induced edema and weight gain (Kang et al., 2006; Ruaño et al., 2009; Bailey et al., 2010; Dawed et al., 2016).

Metformin

Metformin is the first-line therapy for T2D. Around 30% of metformin treated subjects experience gastrointestinal (GI) side effects manifested as nausea, indigestion, abdominal cramps,

bloating, diarrhea, or combination of these (**Table 1**) (Garber et al., 1997; Hirst J. A. et al., 2012). Metformin is an organic cation, and carrier proteins mediate its oral absorption, hepatic uptake, and renal elimination. Several solute carrier transporters, expressed in the membranes of the enterocytes, could be involved in the absorption of metformin from the intestinal lumen, including organic cation transporter (OCT) 1, plasma membrane monoamine transporter (PMAT), carnitine/cation transporter 1, OCT3 (encoded by *SLC22A3*), and serotonin reuptake transporter (SERT) (Han et al., 2015). Genetic variants in genes encoding these transporters have been reported in five articles (**Table 3**) (Tarasova et al., 2012; Dujic et al., 2015, 2016a,b; Dawed et al., 2019).

Association between genetic variants in *SLC22A1* (a gene encoding OCT1), and GI intolerance related to metformin therapy have been reported in three studies (Tarasova et al., 2012; Dujic et al., 2015, 2016a). A study conducted using the GoDARTS cohort (Hébert et al., 2018), in 251 metformin-intolerant and 1,915 metformin-tolerant individuals showed that the presence of two or more reduced-function alleles at R61C, C88R, G401S, M420del, or G465R increased the odds of GI side effects of metformin by more than 2-fold (Dujic et al., 2015). This effect was over 4-fold with concomitant use of OCT1-inhibiting drugs. The findings were replicated in another prospective observational cohort study from Bosnia and Herzegovina that included 92

TABLE 2 | Description of included studies.

References	Country	Study drug	Study period	Parent study	Population	Gene	Comparators	N
Dawed et al. (2019)	Multinational (Europe)	Metformin		IMI DIRECT	White Europeans aged between 18 and 90 years	<i>SLC29A4</i>	Metformin-intolerant Metformin-tolerant	286 1,128
Dujic et al. (2015)	Scotland, UK	Metformin	1 January 1994–1 June 2011.	GoDARTS	White Europeans	<i>SLC22A1</i>	metformin-intolerant Metformin- tolerant	251 1,915
Dujic et al. (2016b)	Scotland, UK	Metformin	1 January 1994–1 June 2011.	GoDARTS	White Europeans	<i>SLC6A4</i> <i>SLC22A1</i>	Metformin-tolerant Metformin-intolerant	1,356 164
Dujic et al. (2016a)	Bosnia and Herzegovina	Metformin			T2D diagnosis after the age of 35 years	<i>SLC22A1</i>	Metformin-tolerant Metformin-intolerant	49 43
Tarasova et al. (2012)	Latvia	Metformin	from 2003 to 2010	LGDB	Subjects with T2D older than 18 years	<i>SLC22A1</i> , <i>SLC22A2</i> , <i>SLC47A1</i>	Metformin-tolerant Metformin-intolerant	193 53
Gökalp et al. (2011)	Turkey	Glimepiride Gliclazide Glipizide	2003 and 2005	None	Subjects with T2D treated with SU for at least 3 months.	<i>CYP2C9</i> <i>CYP2C19</i> <i>CYP2C8</i>	Without hypoglycemia With hypoglycemia	93 15
Dujic et al. (2018)	Scotland	Glibenclamide Gliclazide Glimepiride Glipizide	1994–2010	GoDARTS	Subjects with T2D who were incident users of SU	<i>POR</i> <i>CYP2C9</i>	Without hypoglycemia With hypoglycemia	311 69
Holstein et al. (2011)	Germany	Glimepiride Glibenclamide Gliquidone.	1 January 2000 and 31 December 2009	None	Subjects with T2D treated with SU	<i>CYP2C9</i>	Without severe hypoglycemia With severe hypoglycemia	101 102
Holstein et al. (2005)	Germany	Glibenclamide Glimepiride	January 2000 and 31 December 2003	None	Subjects with T2D treated with SU	<i>CYP2C9</i>	Without severe hypoglycemia With severe hypoglycemia	337 20
Holstein et al. (2012)	Germany	Glimepiride Glibenclamide Gliquidone	January 2000–31 December 2010	None	Subjects with T2D admitted to the emergency department	<i>ABCC8</i>	Without hypoglycemia With hypoglycemia	100 111

(Continued)

TABLE 2 | Continued

References	Country	Study drug	Study period	Parent study	Population	Gene	Comparators	N
Sato et al. (2010)	Japan	Glimepiride	January 2005 and	None	Subjects with T2D	<i>ABCC8</i>	Without hypoglycemia	32
		Glibenclamide	October 2009		treated with Sus		With hypoglycemia	125
Ragia et al. (2012)	Greece	Glimepiride	February	None	Subjects with T2D	<i>KCNJ11</i>	Without hypoglycemia	84
		Gliclazide	2007–September		treated with SU		With hypoglycemia	92
			2008					
Ragia et al. (2014)	Greece	Glimepiride	February	None	Subjects with T2D	<i>CYP2C9</i>	Without hypoglycemia	84
		Gliclazide	2007–September		treated with SU		With hypoglycemia	92
			2008					
Ragia et al. (2009)	Greece	Glimepiride	February	None	Subjects with T2D	<i>CYP2C9</i>	Without hypoglycemia	84
		Gliclazide	2007–September		treated with SU		With hypoglycemia	92
			2008					
Ruaño et al. (2009)	USA	Rosiglitazone	Between February	None	Subjects with T2D	For BMI: <i>ADORA1, PKM2,</i>		87
		Pioglitazone	and June 2007		treated with	<i>ADIPOR2, UCP2, APOH,</i>		
					rosiglitazone or	<i>IRS1, LIPA, RARB, and</i>		
					pioglitazone for ≥ 4	<i>CHRM3</i>		
					months	For Edema: <i>NPY, GYS1,</i>		
						<i>CCL2, OLR1, GHRH,</i>		
						<i>ADRB1, ACACB, SCARB2,</i>		
						<i>HRH3 and ACE</i>		
Kang et al. (2006)	South Korea	Rosiglitazone		None	Subjects with T2D	<i>PLIN</i>		160
					aged between 35			
					and 80 years			
Dawed et al. (2016)	Scotland, UK	Rosiglitazone			Subjects with T2D	<i>CYP2C8</i>		833
		Pioglitazone			treated with TZD			
Bailey et al. (2010)	Multinational	Rosiglitazone		DREAM	Subjects with T2D	<i>NFATC2</i>	Rosiglitazone	965
	(21 countries)	Placebo			≥ 30 years of age		Placebo	956

TABLE 3 | Association between metformin and selected SNPs for the incidence of GI adverse outcomes.

References	Outcome measure	Drug (n)			Gene	SNP/genotype	Conclusion
		Drug	Tolerant	Intolerant			
Dawed et al. (2019)	Incidence of GI adverse effects	Metformin	1,128	286	<i>SLC29A4</i>	rs3889348G>A	The G allele at rs3889348 (<i>SLC29A4</i>) was associated with higher odds of gastrointestinal intolerance (OR 1.34 [1.09–1.65], $P = 0.005$).
Dujic et al. (2015)	Incidence of GI adverse effects	Metformin	1,915	251	<i>SLC22A1</i>	R61C C88R G401S M420del G465R	Compared to carriers of one or no deficient allele, carriers of two reduced-function OCT1 alleles had higher odds of intolerance (OR 2.41 [1.48–3.93], $P < 0.001$).
Dujic et al. (2016b)	Incidence of GI adverse effects	Metformin	1,356	164	<i>SLC6A4</i>	L*L* L*S* S*S*	Each S* alleles was associated with higher odds of metformin intolerance (OR = 1.28 [1.01–1.63], $P = 0.04$). Multiplicative interaction between <i>SLC6A4</i> and <i>SLC22A1</i> ($P = 0.003$)
Dujic et al. (2016a)	Incidence of GI adverse effects	Metformin	49	43	<i>SLC22A1</i>	R61C M420del	Each OCT1 reduced-function allele was associated with higher odds of GI side effects (OR = 2.31 [1.07–5.01], $P = 0.034$).
Tarasova et al. (2012)	Incidence of GI side effects	Metformin	193	53	<i>SLC22A1</i> <i>SLC22A2</i> <i>SLC47A1</i>	rs12208357A>G rs34059508T>C rs628031A>G rs72552763D>I rs36056065I>D rs316019T>G rs2289669A>G	Each A allele at rs628031 was associated with lower odds of intolerance (OR = 0.39 [0.19–0.82], $P = 0.01$) Each 8 bp insertion at rs36056065 was associated with lower odds of intolerance (OR = 0.41 [0.23–0.72], $P = 0.01$)

newly diagnosed subjects in the first 6 months of metformin treatment (Dujic et al., 2016a). Likewise, Tarasova et al. showed significant associations between a SNP (rs628031) and an 8 bp insertion (rs36056065) in the *SLC22A1*, with GI side effects of metformin (Tarasova et al., 2012).

Dawed et al. reported association between rs3889348, a variant that alters intestinal expression of the *SLC9A4* (a gene encoding PMAT), with metformin related GI intolerance in 286 severe intolerant and 1,128 tolerant subjects. The G allele that reduces expression of *SLC29A4* was associated with 34% higher odds of intolerance. Concomitant administration of metformin transporter inhibiting drugs exacerbate GI intolerance by more than 3-folds (Dawed et al., 2019).

Considering involvement of serotonin reuptake transporter (SERT) in metformin intestinal absorption, Dujic et al. investigated association between the low-expressing S* allele derived from a composite SERT (*SLC6A4*)-5-HTTLPR/rs25531 genotypes and metformin intolerance. In this study, each S* allele

was associated with 30% higher odds of intolerance. Interestingly, a multiplicative interaction between OCT1 and SERT genotypes was observed (Dujic et al., 2016b). Carriers of reduced function alleles in OCT1 at the background of the wild type SERT (L*L*) genotype had greater odds of intolerance (OR 9.25 [3.18–27.0]) compared to carriers of the S* allele.

Sulfonylureas

Sulfonylureas were the first oral glucose-lowering therapy introduced into clinical practice and along with metformin, are the most prescribed drugs for the management of T2D (Inzucchi et al., 2015). SU are transported into the liver by OATP1B1 (encoded by *SLCO1B1*) and metabolized mainly by the polymorphic CYP2C9 enzyme and to a lesser extent by CYP2C19 enzyme (Becker et al., 2008). CYP2C9*2 (R144C, rs1799853) and CYP2C9*3 (I359L, rs1057910) are the two most common variants that have been associated with poor metabolism of SU (Semiz et al., 2010). Sulfonylureas induce glucose-independent

TABLE 4 | Association between sulfonylureas and selected SNPs for the incidence of hypoglycemia.

References	Outcome measure	Sulfonylurea drug (%)			Gene	Genotypes	Conclusion
		Drug	Controls	Cases			
Gökalp et al. (2011)	Incidence of mild hypoglycemia	Glimepiride Gliclazide Glipizide	44 (47%) 41 (44%) 8 (9%)	6 (40%) 5 (33%) 4 (27%)	<i>CYP2C9</i>	<i>CYP2C9</i> *2 <i>CYP2C9</i> *3	In the gliclazide group a significant association between <i>CYP2C9</i> genotypes and hypoglycemic attacks were observed ($P = 0.035$).
Dujic et al. (2018)	Incidence of SU-induced hypoglycemia	Glibenclamide Gliclazide Glimepiride Glipizide	5 (1.6%) 254 (81.7%) 3 (1.0%) 49 (15.8%)	2 (2.9%) 53 (76.8%) 4 (5.8%) 10 (14.5%)	<i>POR</i> <i>CYP2C9</i>	<i>POR</i> *28 <i>CYP2C9</i> *2 <i>CYP2C9</i> *3	The number of <i>CYP2C9</i> deficient alleles increased the odds of hypoglycemia nearly 3-fold (OR, 2.81; 95% CI, 1.30–6.09; $P = 0.009$) only at the <i>POR</i> *1/*1 genotype background. Statistically significant interaction between <i>POR</i> and <i>CYP2C9</i> genotypes ($P = 0.007$).
Holstein et al. (2011)	Severe hypoglycemia	Glimepiride Glibenclamide Gliquidone	81 (80.2%) 18 (17.8%) 2 (2%)	76 (74.5%) 25 (24.5%) 1 (1.0%)	<i>CYP2C9</i>	<i>CYP2C9</i> *1 <i>CYP2C9</i> *2 <i>CYP2C9</i> *3	There was no overrepresentation of the <i>CYP2C9</i> *2/*2, *2/*3, and *3/*3 variants in the SH group (2%) compared with the control group (5%).
Holstein et al. (2005)	Severe hypoglycemia	Glimepiride Glibenclamide	337 337	20 20	<i>CYP2C9</i>	<i>CYP2C9</i> *1 <i>CYP2C9</i> *2 <i>CYP2C9</i> *3	The <i>CYP2C9</i> genotypes *3/*3 and *2/*3 that are predictive of low enzyme activity were more common in the hypoglycemic group than in the comparison groups (10 vs. <2%, OR 5.2; 95% CI, 1.01, 27).
Holstein J. D. et al. (2012)	Severe hypoglycemia	Glimepiride Glibenclamide Gliquidone	80 18 2	82 28 1	<i>ABCC8</i>	Ser1369Ala	Ser1369Ala variant in <i>ABCC8</i> does not affect the response to sulfonylurea treatment and so, is not a major player in the etiology of severe hypoglycemia.
Sato et al. (2010)	Severe hypoglycemia	Glimepiride Glibenclamide	32 32	125 125	<i>ABCC8</i>	Ser1369Ala	No significant differences in the distribution of the Ser1369Ala genotype between patients with or without severe hypoglycemia ($p = 0.26$).
Ragia et al. (2012)	Mild hypoglycemia	Glimepiride Gliclazide	4 10	80 12	<i>KCNJ11</i>	E23K	<i>KCNJ11</i> E23K polymorphism did not affect hypoglycemia risk.
Ragia et al. (2014)	Mild hypoglycemia	Glimepiride Gliclazide	74 10	80 12	<i>CYP2C9</i> <i>POR</i>	<i>CYP2C9</i> *1 <i>CYP2C9</i> *2 <i>CYP2C9</i> *3 <i>POR</i> *1 <i>POR</i> *28	<i>POR</i> *28 allele was not associated with severe hypoglycemia. <i>CYP2C9</i> *2 allele increased the risk of hypoglycemia by more than 3 times (OR: 3.218, $p = 0.031$). <i>POR</i> *28 allele is masking the association of <i>CYP2C9</i> *2 allele with severe hypoglycemia.
Ragia et al. (2009)	Mild hypoglycemia	Glimepiride Gliclazide	74 10	80 12	<i>CYP2C9</i>	<i>CYP2C9</i> *1 <i>CYP2C9</i> *2 <i>CYP2C9</i> *3	The presence of <i>CYP2C9</i> *3 allele puts subjects with T2D at higher risk of hypoglycemia when receiving the SU.

insulin release from the pancreatic β -cells by binding to the ATP-sensitive potassium (KATP) channels, SUR1 and Kir6.2, that are encoded by the *ABCC8* and *KCNJ11* genes, respectively.

Hypoglycemia is the most common adverse effect of SU. In a systematic review consisting of 22 randomized controlled trials,

10.1 and 5.9% of SU treated subjects experienced hypoglycemia as defined by blood glucose levels of ≤ 3.1 or ≤ 2.8 mmol/L, respectively (Schopman et al., 2014). Severe hypoglycemia with SU therapy is less common, with reported incidence of 0.8%. SU treatment also results in weight gain of 1–3 kg (Schopman et al.,

TABLE 5 | Association between thiazolidinediones and selected SNPs for the incidence of weight gain and edema.

References	Outcome measure	Drug	Sample size	Gene	SNP/genotype	Conclusion
Dawed et al. (2016)	Weight gain	Rosiglitazone Pioglitazone	519 273	<i>CYP2C8</i> <i>SLCO1B1</i>	<i>CYP2C8</i> *3 (rs10509681) 521T>C (rs4149056)	The <i>CYP2C8</i> *3 variant was associated with less weight gain ($P = 0.02$).
Bailey et al. (2010)	Edema	Rosiglitazone	965	GWAS	GWAS	rs6123045 an intronic SNP in the <i>NFATC2</i> was significantly associated with edema (OR 1.89 [95% CI 1.47–2.42]; $P = 5.32 \times 10^{-7}$)
Ruaño et al. (2009)	BMI	Rosiglitazone Pioglitazone	87	<i>ADORA1</i> <i>PKM2</i> <i>ADIPOR2</i> <i>UCP2</i> <i>APOH</i>	rs903361 rs2856929 rs7975375 rs660339 rs8178847	<i>ADORA1</i> -rs903361 was significantly associated with weight gain $P < 0.0003$)
Kang et al. (2006)	Weight gain	Rosiglitazone	160	<i>PLIN</i>	6209T>C 11482G>A 13041A>G 14995A>T	The A allele at 11482G>A was associated with less weight gain (GG, 1.33 ± 1.59 kg; GA, 0.85 ± 1.89 kg; and AA, 0.03 ± 1.46 kg; $P = 0.010$)

2014). Risk of hypoglycemia and weight gain may vary with age, gender, renal function, disease progression, drug exposure, and genetic constitution.

In this systematic review, we have included studies that investigated association between genetic variants in genes, *CYP2C9* and *ABCC8/KCNJ11*, that encode *CYP2C9* and *SUR1/Kir6.2* with risk of hypoglycemia (Holstein et al., 2005, 2011, 2012; Ragia et al., 2009, 2012, 2014; Gökalp et al., 2011) (Table 4). An association between reduced function *CYP2C9**2 and *CYP2C9**3 alleles with higher risk of SU related hypoglycemia was reported confirming earlier functional and pharmacokinetic data (Ragia et al., 2009; Gökalp et al., 2011). However, another study could not confirm the findings (Holstein et al., 2011). In the later study subjects within the control arm that carry slow metabolizing alleles were found to be treated with significantly lower doses than carriers of the wild type, whereas in the group with severe hypoglycemia, the dose was the same for all genotype groups. Another small study suggested a possible interaction between P450 oxidoreductase (*POR*) and *CYP2C9* genotypes (Ragia et al., 2014), where *POR**28 allele could mask the effect of *CYP2C9**2 allele on sulfonylurea-induced hypoglycemia. Indeed, a bigger study from the GoDARTS cohort confirmed this and therefore it is worth considering *CYP2C9* and *POR* genotypes jointly in studies involving the pharmacogenetics of SU (Dujic et al., 2018).

Three other studies investigated association between two strongly linked non-synonymous polymorphisms, S1369A (rs757110) and E23K (rs5219), in the *ABCC8* and *KCNJ11* genes, respectively with hypoglycemia (Sato et al., 2010; Holstein et al., 2012; Ragia et al., 2012). None of these studies showed statistically significant association between SU treatment and

risk of hypoglycemia suggesting these polymorphisms may not play a major role in the etiology of hypoglycemia.

Thiazolidinediones

Thiazolidinediones are insulin sensitizers that act by increasing the transactivation activity of Peroxisome Proliferators Activated Receptors (PPARs). The clinically used TZDs, rosiglitazone and pioglitazone, suffer from serious side effects. Concerns about the cardiovascular safety of rosiglitazone due to fluid retention led suspension in the European market and several restrictions in the US (Woodcock et al., 2010; Shukla and Kalra, 2011). Unlike rosiglitazone, pioglitazone did not show any risk of cardiovascular side effects. However, concerns were raised on the apparent risk of bladder cancer with pioglitazone and hence it is not recommended in people with active or prior history of bladder cancer (Shukla and Kalra, 2011). TZDs are associated with an average of 2–4 kg weight gain in the first year of management (Yki-Järvinen, 2004). In addition, these agents result in peripheral edema in 4–6% (Graham et al., 2010).

This systematic review identified four articles that assessed association between genetic variants in candidate genes and weight gain and/or oedema after treatment with TZDs (Kang et al., 2006; Ruaño et al., 2009; Bailey et al., 2010; Dawed et al., 2016) (Table 5). A *post-hoc* analysis from the DREAM (Diabetes REDuction Assessment with ramipril and rosiglitazone Medication) trial that consist of 4,197 participants showed higher rate of rosiglitazone-induced edema (OR = 1.89 [95% CI = 1.47–2.42], $P = 0.017$) in subjects homozygous for the C allele at rs6123045, a variant at the Nuclear Factor of Activated T-cells, Cytoplasmic, Calcineurin-Dependent 2 (*NFATC2*) locus (Bailey et al., 2010). We have previously showed association between the *CYP2C8**3 variant with less weight gain compared to the wild

type ($P = 0.02$) in the GoDARTS (Dawed et al., 2016). Another study by Ruaño et al. investigated 384 SNPs in 87 subjects treated with TZDs and reported significant association between an intronic SNP, rs903361, in Adenosine A1 Receptor (*ADORA1*) and BMI after correcting for multiple testing (Ruaño et al., 2009). The A allele at Perilipin 1, PLIN 11482G>A (rs894160), was also associated with less weight gain in Korean subjects treated with rosiglitazone compared to the G allele (Kang et al., 2006). Given these findings replicate in well-powered independent studies, we could potentially identify individuals who can benefit from the considerable therapeutic advantages of TZDs and who are least at risk for the side effects.

DISCUSSION

This systematic review considers the adverse effects of glucose lowering drugs and their relationship to genetic variability. It presents the up-to-date knowledge of genetic variants that could influence ADRs related to drugs for the management of type 2 diabetes. Comprehensive understanding of genetic variants associated with ADRs have clinical utility in risk stratification of patients and precision therapeutics. Although numerous associations of genetic variants with ADR have been discovered, replication has proven difficult. This could mainly be due to a smaller sample which may not be sufficiently powered to detect the desired effect, the lack of consistent phenotypic definitions used, presence of possible drug-drug interactions, and related comorbidities.

This systematic review suggests that at present the clinical translation of genetic variants associated with ADR in diabetes therapy are limited.

Inter-ethnic differences in the susceptibility to ADRs and response to drugs are under-investigated. However, inter-ethnic differences have long been recognized as a crucial aspect of the genetics of variation in drug response. This could be due to differing background frequencies of risk alleles. For example, the frequency of 420del allele, that causes reduced OCT1 function and associated with higher odds of GI side effects of metformin, is much higher amongst European (~17%) than East Asian (~0.5%) or African (~6%) populations (Karczewski et al., 2020). The same is true for the loss of function variant, CYP2C9*3 (European ~6.7%, African ~1.3%, South Asian 1.2%) (Karczewski et al., 2020).

It is also likely that adverse drug reactions are polygenic. In polygenic effects, risk is conferred by combinations between several variants each of which could have small individual effects that are summarized as polygenic risk scores. We have previously shown a better prediction of metformin-induced GI intolerance by combining SNPs in the OCT1 (*SLC22A1*) and PMAT (*SLC29A4*) (Dawed et al., 2019), pioglitazone-related weight gain and SNPs in the *SLCO1B1* and *CYP2C9* (Dawed et al., 2016). Comprehensive studies encompassing data from hypothesis free genome-wide associations are required to identify susceptibility loci. In addition, next generation sequencing that allows the analysis of rare variants that have been postulated

to have larger effects are likely to reveal functionally relevant genomic variations for ADRs.

Clinical, anthropometric, and environmental factors such as age, sex, weight, concomitant use of other drugs was also shown to contribute to ADRs in diabetes. Older people, women, and concomitant use of gut metformin transporter inhibiting drugs were previously shown to increase the likelihood of GI side effects of metformin (Dujic et al., 2015; Dawed et al., 2019). In addition, longer diabetes duration, impaired renal function, lower body mass index, lower triglyceride levels and old age were identified as major risk factors for hypoglycemia in people with type 2 diabetes (Schloot et al., 2016).

Even though this review is comprehensive, it is subjected to limitations. First, the studies included were heterogeneous in design with regards to treatment, adverse effect outcomes definitions, and population (ethnicity). The timing to measure primary endpoint (adverse effects of oral glucose-lowering agents) is also not uniform.

Poor adherence to treatment is a well-known phenomenon in patients with diabetes and is associated with inadequate glycaemic control leading to rapid disease progression and complications (Polonsky and Henry, 2016). Moderate and severe ADRs such as hypoglycemia and GI intolerance are previously shown to be key contributors of poor adherence in diabetes.

In conclusion, there are few pharmacogenomic studies of ADRs in type 2 diabetes that have been undertaken. Most of the studies have not been externally replicated, except OCT1 and metformin induced GI intolerance, CYP2C9 and SU-induced hypoglycemia. In the future, well-powered pharmacogenomic studies in T2D should collect standardized ADR data in multi-ethnic populations.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

AMB and AYD conceived and designed this research, executed the analysis procedure, and analyzed the results. AMB, MKS, and AYD contributed to the writing of the manuscript. All authors reviewed the manuscript.

FUNDING

This work was partly supported by the internal Global Challenges Research Fund (GCRF) from the University of Dundee and the National Institute for Health Research (NIHR) using Official Development Assistance funding (INSPIRED 16/136/102).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2021.675053/full#supplementary-material>

REFERENCES

- Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., et al. (2016). Long-term metformin use and vitamin b12 deficiency in the diabetes prevention program outcomes study. *J. Clin. Endocrinol. Metab.* 101, 1754–1761. doi: 10.1210/jc.2015-3754
- Bailey, C. J., and Turner, R. C. (1996). Metformin. *N. Engl. J. Med.* 334, 574–579. doi: 10.1056/NEJM199602293340906
- Bailey, S. D., Xie, C., Do, R., Montpetit, A., Diaz, R., Mohan, V., et al. (2010). Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. *Diabetes Care* 33, 2250–2253. doi: 10.2337/dc10-0452
- Becker, M. L., Visser, L. E., Trienekens, P. H., Hofman, A., van Schaik, R. H., and Stricker, B. H. (2008). Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. *Clin. Pharmacol. Ther.* 83, 288–292. doi: 10.1038/sj.clpt.6100273
- Bell, D. S. (2010). Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. *South. Med. J.* 103, 265–267. doi: 10.1097/SMJ.0b013e3181ce0e4d
- Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., et al. (2020). 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 63, 221–228. doi: 10.1007/s00125-019-05039-w
- Davies, E. C., Green, C. F., Mottram, D. R., Rowe, P. H., and Pirmohamed, M. (2010). Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. *Br. J. Clin. Pharmacol.* 70, 749–755. doi: 10.1111/j.1365-2125.2010.03751.x
- Davies, E. C., Green, C. F., Taylor, S., Williamson, P. R., Mottram, D. R., and Pirmohamed, M. (2009). Adverse drug reactions in hospital inpatients: a prospective analysis of 3695 patient-episodes. *PLoS ONE* 4:e4439. doi: 10.1371/journal.pone.0004439
- Dawed, A. Y., Donnelly, L., Tavendale, R., Carr, F., Leese, G., Palmer, C. N., et al. (2016). CYP2C8 and SLC11B1 variants and therapeutic response to thiazolidinediones in patients with type 2 diabetes. *Diabetes Care* 39, 1902–1908. doi: 10.2337/dc15-2464
- Dawed, A. Y., Zhou, K., van Leeuwen, N., Mahajan, A., Robertson, N., Koivula, R., et al. (2019). Variation in the plasma membrane monoamine transporter (PMAT) (Encoded by SLC29A4) and organic cation transporter 1 (OCT1) (Encoded by SLC22A1) and gastrointestinal intolerance to metformin in type 2 diabetes: an IMI DIRECT study. *Diabetes Care* 42, 1027–1033. doi: 10.2337/dc18-2182
- de Jager, J., Kooy, A., Leher, P., Wulffélé M. G., van der Kolk, J., Bets, D., et al. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *Bmj* 340:c2181. doi: 10.1136/bmj.c2181
- Donnelly, L. A., Dennis, J. M., Coleman, R. L., Sattar, N., Hattersley, A. T., Holman, R. R., et al. (2020). Risk of anemia with metformin use in type 2 diabetes: a MASTERMIND study. *Diabetes Care* 43, 2493–2499. doi: 10.2337/dc20-1104
- Ducoffe, A. R., York, A., Hu, D. J., Peretto, D., and Kerns, R. D. (2016). National action plan for adverse drug event prevention: recommendations for safer outpatient opioid use. *Pain Med.* 17, 2291–2304. doi: 10.1093/pm/pnw106
- Dujic, T., Causevic, A., Bego, T., Malenica, M., Velija-Asimi, Z., Pearson, E. R., et al. (2016a). Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. *Diabet. Med.* 33, 511–514. doi: 10.1111/dme.13040
- Dujic, T., Zhou, K., Donnelly, L. A., Leese, G., Palmer, C. N. A., and Pearson, E. R. (2018). Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: a GoDARTS Study. *Diabetes Obes. Metab.* 20, 211–214. doi: 10.1111/dom.13046
- Dujic, T., Zhou, K., Donnelly, L. A., Tavendale, R., Palmer, C. N., and Pearson, E. R. (2015). Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. *Diabetes* 64, 1786–1793. doi: 10.2337/db14-1388
- Dujic, T., Zhou, K., Tavendale, R., Palmer, C. N., and Pearson, E. R. (2016b). Effect of serotonin transporter 5-HTTLPR polymorphism on gastrointestinal intolerance to metformin: a GoDARTS study. *Diabetes Care* 39, 1896–1901. doi: 10.2337/dc16-0706
- Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., and Rohlf, J. L. (1997). Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. *Am. J. Med.* 103, 491–497. doi: 10.1016/S0002-9343(97)00254-4
- Gökalp, O., Gunes, A., Cam, H., Cure, E., Aydin, O., Tamer, M. N., et al. (2011). Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. *Eur. J. Clin. Pharmacol.* 67, 1223–1229. doi: 10.1007/s00228-011-1078-4
- Goodman, L. S. (2017). *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 13 Edn. New York, NY: McGraw-Hill.
- Graham, D. J., Ouellet-Hellstrom, R., MacCurdy, T. E., Ali, F., Sholley, C., Worrall, C., et al. (2010). Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. *Jama* 304, 411–418. doi: 10.1001/jama.2010.920
- Guardado-Mendoza, R., Prioleta, A., Jiménez-Ceja, L. M., Sosale, A., and Folli, F. (2013). The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. *Arch. Med. Sci.* 9, 936–943. doi: 10.5114/aoms.2013.34991
- Han, T. K., Proctor, W. R., Costales, C. L., Cai, H., Everett, R. S., and Thakker, D. R. (2015). Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers. *J. Pharmacol. Exp. Ther.* 352, 519–528. doi: 10.1124/jpet.114.220350
- Hébert, H. L., Shepherd, B., Milburn, K., Veluchamy, A., Meng, W., Carr, F., et al. (2018). Cohort profile: genetics of diabetes audit and research in Tayside Scotland (GoDARTS). *Int. J. Epidemiol.* 47:380-1j. doi: 10.1093/ije/dyx140
- Hirst, J. A., Farmer, A. J., Ali, R., Roberts, N. W., and Stevens, R. J. (2012). Quantifying the effect of metformin treatment and dose on glycemic control. *Diabetes Care* 35, 446–454. doi: 10.2337/dc11-1465
- Holstein, A., Beil, W., and Kovacs, P. (2012). CYP2C metabolism of oral antidiabetic drugs—impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. *Expert Opin. Drug Metab. Toxicol.* 8, 1549–1563. doi: 10.1517/17425255.2012.722619
- Holstein, A., Hahn, M., Patzer, O., Seeringer, A., Kovacs, P., and Stingl, J. (2011). Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. *Eur. J. Clin. Pharmacol.* 67, 471–476. doi: 10.1007/s00228-010-0976-1
- Holstein, A., Plaschke, A., Ptak, M., Egberts, E. H., El-Din, J., Brockmöller, J., et al. (2005). Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. *Br. J. Clin. Pharmacol.* 60, 103–106. doi: 10.1111/j.1365-2125.2005.02379.x
- Holstein, J. D., Kovacs, P., Patzer, O., Stumvoll, M., and Holstein, A. (2012). The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. *Pharmacogenomics* 13, 5–7; author reply 9–10. doi: 10.2217/pgs.11.150
- International Diabetes Federation (2019). *IDF Diabetes Atlas, 9th Edn.* Brussels: International Diabetes Federation.
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., et al. (2015). Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 38, 140–149. doi: 10.2337/dc14-2441
- Jearath, V., Vashisht, R., Rustagi, V., Raina, S., and Sharma, R. (2016). Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction. *J. Pharmacol. Pharmacother.* 7, 41–43. doi: 10.4103/0976-500X.179363
- Juurink, D. N., Gomes, T., Lipscombe, L. L., Austin, P. C., Hux, J. E., and Mamdani, M. M. (2009). Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. *Bmj* 339:b2942. doi: 10.1136/bmj.b2942
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., et al. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N. Engl. J. Med.* 355, 2427–2443. doi: 10.1056/NEJMoa066224
- Kang, E. S., Cha, B. S., Kim, H. J., Kim, H. J., Kim, S. H., Hur, K. Y., et al. (2006). The 11482G > A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. *Diabetes Care* 29, 1320–1324. doi: 10.2337/dc05-2466

- Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., et al. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581, 434–443. doi: 10.1038/s41586-020-2308-7
- Katzung, B. G., Kruidering-Hall, M., and Trevor, A. J. (2019). *Katzung and Trevor's Pharmacology: Examination and Board Review, 12Edn*. New York, NY: McGraw-Hill Companies, Incorporated.
- Madsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., and Holst, J. J. (2011). An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future. *Diabetes Obes. Metab.* 13, 394–407. doi: 10.1111/j.1463-1326.2011.01357.x
- Meneilly, G. S. (2011). Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. *Diabetes Technol. Ther.* 13, 63–65. doi: 10.1089/dia.2010.0105
- Misbin, R. I. (2004). The phantom of lactic acidosis due to metformin in patients with diabetes. *Diabetes Care* 27, 1791–1793. doi: 10.2337/diacare.27.7.1791
- Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., et al. (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *Bmj* 32:15. doi: 10.1136/bmj.329.7456.15
- Polonsky, W. H., and Henry, R. R. (2016). Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. *Patient Prefer. Adherence* 10, 1299–1307. doi: 10.2147/PPA.S106821
- Ragia, G., Petridis, I., Tavridou, A., Christakidis, D., and Manolopoulos, V. G. (2009). Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. *Pharmacogenomics* 10, 1781–1787. doi: 10.2217/pgs.09.96
- Ragia, G., Tavridou, A., Elens, L., Van Schaik, R. H., and Manolopoulos, V. G. (2014). CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. *Exp. Clin. Endocrinol. Diabetes* 122, 60–63. doi: 10.1055/s-0033-1361097
- Ragia, G., Tavridou, A., Petridis, I., and Manolopoulos, V. G. (2012). Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. *Diabetes Res. Clin. Pract.* 98, 119–124. doi: 10.1016/j.diabres.2012.04.017
- Ruaño, G., Bernene, J., Windemuth, A., Bower, B., Wencker, D., Seip, R. L., et al. (2009). Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. *Clin. Chim. Acta* 400, 48–55. doi: 10.1016/j.cca.2008.10.009
- Salvo, F., Moore, N., Arnaud, M., Robinson, P., Raschi, E., De Ponti, F., et al. (2016). Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. *Bmj* 353:i2231. doi: 10.1136/bmj.i2231
- Sato, R., Watanabe, H., Genma, R., Takeuchi, M., Maekawa, M., and Nakamura, H. (2010). ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. *Pharmacogenomics* 11, 1743–1750. doi: 10.2217/pgs.10.135
- Schlott, N. C., Haupt, A., Schütt, M., Badenhoop, K., Laimer, M., Nicolay, C., et al. (2016). Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk? *Diabetes Metab. Res. Rev.* 32, 316–324. doi: 10.1002/dmrr.2722
- Schopman, J. E., Simon, A. C., Hoefnagel, S. J., Hoekstra, J. B., Scholten, R. J., and Holleman, F. (2014). The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. *Diabetes Metab. Res. Rev.* 30, 11–22. doi: 10.1002/dmrr.2470
- Semiz, S., Dujic, T., Ostanek, B., Prnjavorac, B., Bego, T., Malenica, M., et al. (2010). Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. *Bosn J. Basic Med. Sci.* 10, 287–291. doi: 10.17305/bjbm.2010.2662
- Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *Bmj* 350:g7647. doi: 10.1136/bmj.g7647
- Shukla, R., and Kalra, S. (2011). Pioglitazone: Indian perspective. *Indian J. Endocrinol. Metab.* 15, 294–297. doi: 10.4103/2230-8210.85581
- Spector, W. D., Limcangco, R., Furukawa, M. F., and Encinosa, W. E. (2017). The marginal costs of adverse drug events associated with exposures to anticoagulants and hypoglycemic agents during hospitalization. *Med. Care* 55, 856–863. doi: 10.1097/MLR.0000000000000780
- Tarasova, L., Kalnina, I., Geldnere, K., Bumbure, A., Ritenberga, R., Nikitina-Zake, L., et al. (2012). Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. *Pharmacogenet. Genomics* 22, 659–666. doi: 10.1097/FPC.0b013e3283561666
- Winkelmayer, W. C., Setoguchi, S., Levin, R., and Solomon, D. H. (2008). Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. *Arch. Intern. Med.* 168, 2368–2375. doi: 10.1001/archinte.168.21.2368
- Woodcock, J., Sharfstein, J. M., and Hamburg, M. (2010). Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. *N. Engl. J. Med.* 363, 1489–1491. doi: 10.1056/NEJMp1010788
- Yki-Järvinen, H. (2004). Thiazolidinediones. *N. Engl. J. Med.* 351, 1106–1118. doi: 10.1056/NEJMra041001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Baye, Fanta, Siddiqui and Dawed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.